KOD vs. FATE, HLVX, ITOS, TSHA, VALN, EXAI, KYTX, ADPT, CABA, and ALEC
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Fate Therapeutics (FATE), HilleVax (HLVX), iTeos Therapeutics (ITOS), Taysha Gene Therapies (TSHA), Valneva (VALN), Exscientia (EXAI), Kyverna Therapeutics (KYTX), Adaptive Biotechnologies (ADPT), Cabaletta Bio (CABA), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.
Fate Therapeutics (NASDAQ:FATE) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk.
97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 5.0% of Fate Therapeutics shares are held by insiders. Comparatively, 45.3% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Fate Therapeutics currently has a consensus target price of $6.58, suggesting a potential upside of 78.89%. Kodiak Sciences has a consensus target price of $5.50, suggesting a potential upside of 72.96%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Fate Therapeutics is more favorable than Kodiak Sciences.
Kodiak Sciences has a net margin of 0.00% compared to Kodiak Sciences' net margin of -2,933.79%. Kodiak Sciences' return on equity of -46.49% beat Fate Therapeutics' return on equity.
In the previous week, Fate Therapeutics had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Kodiak Sciences. Fate Therapeutics' average media sentiment score of 0.94 beat Kodiak Sciences' score of 0.64 indicating that Kodiak Sciences is being referred to more favorably in the news media.
Fate Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500.
Fate Therapeutics received 461 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 68.62% of users gave Fate Therapeutics an outperform vote while only 28.13% of users gave Kodiak Sciences an outperform vote.
Fate Therapeutics has higher revenue and earnings than Kodiak Sciences. Fate Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Fate Therapeutics beats Kodiak Sciences on 12 of the 17 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
